Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | F3 | P13726 | 2/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.65 |
| ▸ | BACE1 | P56817 | 4/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3440661 | 1.00 | GSK3B (1.00) | GSK3BRAB9ANPC1F3HDAC3 | |
| SCHEMBL10348539 | 0.93 | GSK3B (0.87) | GSK3BRAB9ANPC1F3HDAC3 | |
| SCHEMBL28550343 | 0.93 | GSK3B (0.87) | GSK3BRAB9ANPC1F3HDAC3 | |
| SCHEMBL11549072 | 0.93 | GSK3B (0.87) | GSK3BRAB9ANPC1F3HDAC3 | |
| SCHEMBL11549066 | 0.93 | GSK3B (0.87) | GSK3BRAB9ANPC1F3HDAC3 | |
| SCHEMBL14864159 | 0.93 | GSK3B (0.87) | GSK3BRAB9ANPC1F3HDAC3 | |
| SCHEMBL11778837 | 0.93 | GSK3B (0.87) | GSK3BRAB9ANPC1F3HDAC3 | |
| SCHEMBL10348538 | 0.93 | GSK3B (0.87) | GSK3BRAB9ANPC1F3HDAC3 | |
| SCHEMBL9414062 | 0.90 | GSK3B (0.81) | GSK3BRAB9ANPC1F3HDAC3 | |
| SCHEMBL9414059 | 0.90 | GSK3B (0.81) | GSK3BRAB9ANPC1F3HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149499-A1 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | BONAFIDE HEALTH, LLC | 2023-05-18 | — | — | US | disclosed |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC UNM (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160008297-A1 | COMPOUNDS FOR PREVENTING, REDUCING AND/OR ALLEVIATING ITCHY SKIN CONDITION(S) | B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG (DE) | 2016-01-14 | — | — | US | disclosed |
| US-20160008297-A1 | COMPOUNDS FOR PREVENTING, REDUCING AND/OR ALLEVIATING ITCHY SKIN CONDITION(S) | B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG (DE) | 2016-01-14 | — | — | US | disclosed |
| US-20160008297-A1 | COMPOUNDS FOR PREVENTING, REDUCING AND/OR ALLEVIATING ITCHY SKIN CONDITION(S) | B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG (DE) | 2016-01-14 | — | — | US | disclosed |
| US-9187397-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2015-11-17 | — | — | US | disclosed |
| US-9074238-B2 | Methods for enhancing neprilysin activity and degrading amyloid-beta peptides and oligomers in a subject with Alzheimer's disease | ACADEMIA SINICA (TW) | 2015-07-07 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130102498-A1 | COMPOSITIONS AND METHODS FOR DETECTING AMYLOID-BETA-DEGRADING ENZYME ACTIVITY | ACADEMIA SINICA (TW) | 2013-04-25 | — | — | US | disclosed |
| US-8410177-B2 | Curcumin derivatives | INDIAN INSTITUTE OF TECHNOLOGY BOMBAY (IN) | 2013-04-02 | — | — | US | disclosed |
| WO-2012143576-A2 | COMPOUNDS FOR PREVENTING, REDUCING AND/OR ALLEVIATING ITCHY SKIN CONDITION(S) | SYMRISE AG (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2011080550-A1 | CURCUMIN DERIVATIVES | INDIAN INSTITUTE OF TECHNOLOGY BOMBAY (IN) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160276-A1 | CURCUMIN DERIVATIVES | EMPIRE TECHNOLOGY DEVELOPMENT LLC | 2011-06-30 | — | — | US | disclosed |
| US-7807230-B2 | Curcumin and curcuminoid compounds, and use thereof as photosensitizers of onium salts | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807230-B2 | Curcumin and curcuminoid compounds, and use thereof as photosensitizers of onium salts | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2010-10-05 | — | — | US | disclosed |
| US-20080260960-A1 | Curcumin and Curcuminoid Compounds, and Use Thereof as Photosensitizers of Onium Salts | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080260960-A1 | Curcumin and Curcuminoid Compounds, and Use Thereof as Photosensitizers of Onium Salts | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2008-10-23 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149499-A1 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | TAC3, PTGER3, TRPV3 | GSK3B 3371/4885RAB9A 2762/4885NPC1 1302/4885 |
| US-20110160276-A1 | CURCUMIN DERIVATIVES | CBR1, HMOX2, PTGS2 | GSK3B 4405/4885RAB9A 2705/4885NPC1 2404/4885 |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | GSK3B 2812/4885RAB9A 2062/4885NPC1 275/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | GSK3B 2812/4885RAB9A 2062/4885NPC1 275/4885 |
| US-20160008297-A1 | COMPOUNDS FOR PREVENTING, REDUCING AND/OR ALLEVIATING ITCHY SKIN CONDITION(S) | TRPV2, TRPV1, TRPM2 | GSK3B 1637/4885RAB9A 2205/4885NPC1 958/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | GSK3B 2812/4885RAB9A 2062/4885NPC1 275/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | GSK3B 3461/4885RAB9A 2661/4885NPC1 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.